DomPachino (@DomPachino)

#BIGPHARMA #PATENTS Generic versions of Ozempic went on sale this week in Canada — somehow the world’s second-largest GLP-1 market — raising questions about whether Novo Nordisk’s failure to renew its Canadian patent and prevent the entry of generic companies into the country was a bit of cunning corporate strategy or an expensive oversight... https://www.semafor.com/article/05/21/2026/novo-nordisk-lets-canadian-patent-expire